Drug Trial Radar · NCT04740307
Safety and Efficacy of Coformulated Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080/MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)
Last checked: Nov 19, 2026Latest source record: Jun 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
Mar 16, 2021
Primary completion
Jul 29, 2025
Study completion Jul 29, 2025
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety and efficacy of fixed dose coformulated pembrolizumab/quavonlimab (MK-1308A) plus lenvatinib in a first line (1L) hepatocellular carcinoma (HCC) setting. No hypothesis testing will be performed.
Conditions
- Advanced Hepatocellular Carcinoma
Interventions
Pembrolizumab/QuavonlimabBiological
Pembrolizumab/Quavonlimab (400 mg/25 mg) administered via IV infusion Q6W.
LenvatinibDrug
Lenvatinib 12 mg (body weight \[BW\] ≥60 kg) or 8 mg (BW \<60 kg) administered orally every day (QD).
PembrolizumabBiological
Pembrolizumab (400 mg) administered via IV infusion Q6W, in the event of intolerable toxicity to pembrolizumab/quavonlimab.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With a Dose-Limiting Toxicity (DLT) in the Safety Lead-in PhaseTime frame: 3 weeks
- Number of Participants With ≥1 Adverse Event (AE)Time frame: Up to approximately 44 months
- Number of Participants With ≥1 Serious Adverse Event (SAE)Time frame: Up to approximately 44 months
- Number of Participants With ≥1 Immune-related AE (irAE)Time frame: Up to approximately 44 months
- Number of Participants With ≥1 Hepatic AETime frame: Up to approximately 44 months
- Number of Participants Discontinuing Study Treatment Due to an AETime frame: Up to approximately 40 months
- Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 51 months
Locations
40 sites in 9 countries. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center ( Site 0002)
Duarte, California
Johns Hopkins Hospital-Sidney Kimmel Comprehensive Cancer Center - GI and Immunology ( Site 0013)
Baltimore, Maryland
Icahn School of Medicine at Mount Sinai ( Site 0009)
New York, New York
Oregon Health and Science University ( Site 0006)
Portland, Oregon
Charleston Oncology ( Site 0003)
Charleston, South Carolina
Blue Ridge Cancer Care ( Site 0008)
Roanoke, Virginia
Virginia Mason Medical Center ( Site 0004)
Seattle, Washington
Anhui Provincial Hospital ( Site 0113)
Hefei, Anhui, China
Beijing Cancer hospital-Department of Hepato-Pancreato-Biliary Surgery II ( Site 0107)
Beijing, Beijing Municipality, China
Fuzhou General hospital of Nanjing Military Command-Oncology Department ( Site 0105)
Fuzhou, Fujian, China
Southern Medical University Nanfang Hospital-Liver Cancer Department ( Site 0106)
Guangzhou, Guangdong, China
Wuhan Union Hospital Cancer Center ( Site 0108)
Wuhan, Hubei, China
Hunan Cancer Hospital-intervention department ( Site 0109)
Changsha, Hunan, China
The First Affiliated Hospital of Xian Jiaotong University ward1 depattment of medical oncology ( Sit
Xi'an, Shaanxi, China
Zhongshan Hospital,Fudan University ( Site 0103)
Shanghai, Shanghai Municipality, China
Huashan Hospital Affiliated Fudan University-Surgery Department ( Site 0118)
Shanghai, Shanghai Municipality, China
Ospedale San Raffaele-Oncologia Medica ( Site 0227)
Milan, Italy
Istituto Nazionale Tumori IRCCS Fondazione Pascale-Department of Abdominal Oncology ( Site 0230)
Naples, Italy
Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0231)
Rozzano, Milano, Italy
Hiroshima University Hospital ( Site 0156)
Hiroshima, Japan
National Cancer Center Hospital East ( Site 0153)
Kashiwa, Chiba, Japan
Toranomon Hospital Kajigaya ( Site 0154)
Kawasaki, Kanagawa, Japan
Kindai University Hospital- Osakasayama Campus-Department of Gastroenterology and Hepatology ( Site
Sayama, Osaka, Japan
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Onkologii i Radioterapii ( Site
Warsaw, Masovian Voivodeship, Poland
Wojewódzki Szpital im. Św. Ojca Pio w Przemyślu ( Site 0249)
Przemyśl, Podkarpackie Voivodeship, Poland
Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0247)
Gdansk, Pomeranian Voivodeship, Poland
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0246)
Koszalin, West Pomeranian Voivodeship, Poland
Asan Medical Center ( Site 0289)
Seoul, South Korea
Seoul National University Bundang Hospital-Medical Oncology ( Site 0290)
Seongnam, Kyonggi-do, South Korea
Samsung Medical Center ( Site 0288)
Seoul, Kyonggi-do, South Korea
Hospital Universitari Vall d'Hebron-Liver Unit - Department of Internal Medicine ( Site 0310)
Barcelona, Spain
Hospital Universitario Central de Asturias-Hepatology ( Site 0309)
Oviedo, Principality of Asturias, Spain
Inselspital Bern-Universitätsklinik für Viszerale Chirurgie und Medizin ( Site 0331)
Bern, Switzerland
Hôpitaux Universitaires de Genève (HUG) ( Site 0335)
Geneva, Canton of Geneva, Switzerland
Cantonal Hospital St.Gallen-Klinik für Gastroenterologie / Hepatologie ( Site 0334)
Sankt Gallen, Canton of St. Gallen, Switzerland
CHUV (centre hospitalier universitaire vaudois) ( Site 0333)
Lausanne, Canton of Vaud, Switzerland
UniversitätsSpital Zürich-Gastroenterologie & Hepatologie ( Site 0332)
Zurich, Canton of Zurich, Switzerland
NATIONAL CHENG-KUNG UNI. HOSP.-Clinical Trial Research Team of Liver Diseases ( Site 0354)
Tainan, Taiwan
National Taiwan University Hospital-Oncology ( Site 0351)
Taipei, Taiwan
Taipei Veterans General Hospital-Division of Gastroenterology & Hepatology, Department of Medicine (
Taipei, Taiwan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.